Inflammation

This article describes food allergy–related service utilization and identifies factors associated with guideline-informed care among Medicaid-enrolled US children with food allergy.

Investigators concluded that use of a new registry could aid in the recruitment of pediatric subjects with severe asthma and the design of future clinical trials for emerging biologics.

The comorbidities associated with atopic dermatitis can be substantial, and the disease can have a significant burden on quality of life, but new biologics and other future treatments may help, said David Pariser, MD, senior physician at Pariser Dermatology Specialists.

The financial, physical, and social burdens of atopic dermatitis can be substantial, especially for patients who had the condition as children into adulthood, said David Pariser, MD, senior physician at Pariser Dermatology Specialists and professor at Eastern Virginia Medical School Department of Dermatology.

Updated guidance in 6 key areas of asthma care focus on improving diagnosis, management, and treatment.

As the only biologic on the market, dupilumab has replaced most of the more traditional treatments for atopic dermatitis, said David Pariser, MD, senior physician at Pariser Dermatology Specialists.

Patients with asthma can improve their disease control and sleep quality, while reducing depression and anxiety through a behavior change intervention aimed at increasing their physical activity.

Expansion of insurance coverage due to the Affordable Care Act led to a reduction in the use of emergency services for patients with asthma in New York City.

Dupilumab, with or without topical corticosteroids, significantly reduced pain and discomfort in patients with moderate to severe atopic dermatitis.

Treatment targets include several interleukins, immunoglobulin E, and alarmins, pointed out Nicola Hanania, MD, MS, pulmonary critical care physician and director, Airway Clinical Research Center, Baylor College of Medicine, Houston.

Overuse of reliever inhalers among adult patients with asthma is prevalent, but does not necessarily translate into higher all-cause health care utilization (HCU), according to a study published in Scientific Reports.

Categorizing by eosinophilic/noneosinophilic subtype enables better targeted treatment, noted Anne Reihman, MD, third-year pulmonary and critical care fellow, University of Colorado, Division of Pulmonary Sciences and Critical Care Medicine.

Vitamin D used as an adjuvant therapy in children with severe atopic dermatitis may improve clinical outcomes, according to a recent study.

Despite the price, adherence to biologics for asthma is usually good because of the effectiveness, said J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology.

When the first biologic to treat asthma was approved by the FDA in 2003, it needed to be administered subcutaneously in the physician’s office. Now, there are 3 options available for at-home use: mepolizumab, benralizumab, and dupilumab.

There are clear differences between the biologics approved to treat asthma, and finding the right one for a patient requires shared decision-making conversations, said J. Allen Meadows, MD.

Atopic dermatitis (AD) has a negative impact on quality of life, and the burden of this disease in adolescents and their parents should be taken into account as part of the management of AD.

Patients with severe asthma are good candidates for biologics, but choosing which biologic requires a shared decision-making conversation, said J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology.

Improvements in lung function occurred as early as 2 weeks after the first dose of treatment.

New data on the long-term efficacy and safety of dupilumab are very reassuring to patients with asthma, explained J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology.

Patients with type 2-high asthma who were being treated with high-dose inhaled corticosteroids (ICS) had reduced exacerbations and improved lung function when they were switched to dupilumab.

The majority of patients with asthma have type 2 inflammation, and the introduction of dupilumab has changed the treatment space for these patients, said Neal Jain, MD, FAAP, FAAAAI.

In the real world, dupilumab has been as effective as the results in clinical trials, and patients are seeing low exacerbation rates, emergency department visits, and hospitalizations, explained Neal Jain, MD, FAAP, FAAAAI.

Following the onset of the coronavirus disease 2019 (COVID-19) pandemic, changes in pediatric asthma health care delivery patterns resulted in reduced hospital admissions and systemic steroid prescriptions in Philadelphia.

The 2-year study will investigate how devices like the Apple Watch and the iPhone can help patients with asthma better manage their condition.